JP2022536476A - Zip6及び/又はzip10に対する抗体を含む抗有糸分裂組成物 - Google Patents
Zip6及び/又はzip10に対する抗体を含む抗有糸分裂組成物 Download PDFInfo
- Publication number
- JP2022536476A JP2022536476A JP2021572873A JP2021572873A JP2022536476A JP 2022536476 A JP2022536476 A JP 2022536476A JP 2021572873 A JP2021572873 A JP 2021572873A JP 2021572873 A JP2021572873 A JP 2021572873A JP 2022536476 A JP2022536476 A JP 2022536476A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- zip6
- zip10
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 title claims description 132
- 101150031731 Slc39a6 gene Proteins 0.000 title claims description 122
- 101150035873 ZIP6 gene Proteins 0.000 title claims description 122
- 102100035243 Zinc transporter ZIP10 Human genes 0.000 title claims description 102
- 101150023714 ZIP10 gene Proteins 0.000 title claims description 97
- 101150117250 slc39a10 gene Proteins 0.000 title claims description 97
- 230000002927 anti-mitotic effect Effects 0.000 title claims description 18
- 230000011278 mitosis Effects 0.000 claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 239000003080 antimitotic agent Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 23
- 239000000833 heterodimer Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 230000004761 fibrosis Effects 0.000 claims description 10
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 101000685848 Homo sapiens Zinc transporter ZIP6 Proteins 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 108091006941 SLC39A10 Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 206010063836 Atrioventricular septal defect Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000026292 Cystic Kidney disease Diseases 0.000 claims description 4
- 206010058314 Dysplasia Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 4
- 208000002260 Keloid Diseases 0.000 claims description 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 4
- 206010054949 Metaplasia Diseases 0.000 claims description 4
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims description 4
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims description 4
- 206010034464 Periarthritis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 238000001211 electron capture detection Methods 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 210000001117 keloid Anatomy 0.000 claims description 4
- 230000015689 metaplastic ossification Effects 0.000 claims description 4
- 206010028537 myelofibrosis Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000017423 tissue regeneration Effects 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims description 2
- 108091007497 betacoronavirus-specific marker domains Proteins 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 155
- 230000000394 mitotic effect Effects 0.000 description 53
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 51
- 239000011701 zinc Substances 0.000 description 51
- 229910052725 zinc Inorganic materials 0.000 description 51
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 36
- 229950006344 nocodazole Drugs 0.000 description 36
- 108010033040 Histones Proteins 0.000 description 30
- 102000006947 Histones Human genes 0.000 description 30
- 102000005465 Stathmin Human genes 0.000 description 14
- 108050003387 Stathmin Proteins 0.000 description 14
- 230000001464 adherent effect Effects 0.000 description 14
- 238000010384 proximity ligation assay Methods 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 108091006550 Zinc transporters Proteins 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 6
- 208000003445 Mouth Neoplasms Diseases 0.000 description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000004688 microtubule Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 206010005949 Bone cancer Diseases 0.000 description 4
- 208000018084 Bone neoplasm Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 208000006332 Choriocarcinoma Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 102100023141 Zinc transporter SLC39A7 Human genes 0.000 description 4
- 208000002458 carcinoid tumor Diseases 0.000 description 4
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 201000000052 gastrinoma Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 101710191105 Zinc transporter SLC39A7 Proteins 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000021953 cytokinesis Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008600 mitotic progression Effects 0.000 description 3
- 230000027498 negative regulation of mitosis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 206010007270 Carcinoid syndrome Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 201000005262 Chondroma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 206010067807 Gingival cancer Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000889890 Homo sapiens Testis-expressed protein 11 Proteins 0.000 description 2
- 101000685830 Homo sapiens Zinc transporter ZIP4 Proteins 0.000 description 2
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
- 206010062038 Lip neoplasm Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 description 2
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000005890 Neuroma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 208000004091 Parotid Neoplasms Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 108091006938 SLC39A6 Proteins 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 206010041329 Somatostatinoma Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 206010043515 Throat cancer Diseases 0.000 description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010062129 Tongue neoplasm Diseases 0.000 description 2
- 206010044002 Tonsil cancer Diseases 0.000 description 2
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046392 Ureteric cancer Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 102100023140 Zinc transporter ZIP4 Human genes 0.000 description 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 208000015322 bone marrow disease Diseases 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000010235 heart cancer Diseases 0.000 description 2
- 208000024348 heart neoplasm Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 208000018819 hormone-resistant breast carcinoma Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 201000006721 lip cancer Diseases 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000022006 malignant tumor of meninges Diseases 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 201000001219 parotid gland cancer Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 201000002511 pituitary cancer Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 201000003437 pleural cancer Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000031877 prophase Effects 0.000 description 2
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 2
- 229960002026 pyrithione Drugs 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 201000006134 tongue cancer Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000011294 ureter cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101100489390 Arabidopsis thaliana ZIP12 gene Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 101000869426 Homo sapiens Metal cation symporter ZIP14 Proteins 0.000 description 1
- 101000685840 Homo sapiens Zinc transporter SLC39A7 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102100032280 Metal cation symporter ZIP14 Human genes 0.000 description 1
- 102100023137 Metal cation symporter ZIP8 Human genes 0.000 description 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150108342 SLC39A12 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101150038440 Slc39a13 gene Proteins 0.000 description 1
- 101150090825 Slc39a5 gene Proteins 0.000 description 1
- 101150052504 Slc39a8 gene Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101150100064 ZIP5 gene Proteins 0.000 description 1
- 102100035257 Zinc transporter ZIP12 Human genes 0.000 description 1
- 102100032279 Zinc transporter ZIP13 Human genes 0.000 description 1
- 102100023142 Zinc transporter ZIP5 Human genes 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027291 mitotic cell cycle Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- XNRNJIIJLOFJEK-UHFFFAOYSA-N sodium;1-oxidopyridine-2-thione Chemical compound [Na+].[O-]N1C=CC=CC1=S XNRNJIIJLOFJEK-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000007046 spindle assembly involved in mitosis Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 101150030145 zip-8 gene Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Description
ZIP6についてはN末端1~325又は1~350及びZIP10については1~407の間で;さらにより好ましくは、ZIP6についてはN末端31~325又は31~344及びZIP10については31~407の間で、前記ZIP6及び/又はZIP10輸送体の(1又は複数の)細胞外ドメイン(ECD)を結合する。さらにより好ましくは、ZIP6についてはN末端アミノ酸93~350及びZIP10については46~395の間で。さらにより理想的には、前記抗体は、ZIP6についてはアミノ酸220~350及びZIP10についてはアミノ酸46~395を結合する。さらにより理想的には、前記抗体は、ZIP6についてはアミノ酸246~259及びZIP10についてはアミノ酸46~59を結合する。
N末端エピトープ(配列番号2 246-EPRKGFMYSRNTNE-259);
N末端及び膜貫通ドメイン1を含む(配列番号3 301-RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN-350);
N末端(配列番号4 303-CLIHTSEKKAEIP-315);
N末端、(配列番号5 129-HSHHNHAASGKNKRKALCPDHDSDSSGKDPRNSQGKGAHRPEHASGRRNVKDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTSKSRVSRLAGRKTNESVSEPRKGFMYSRNTNENPQE-263);
N末端、(配列番号6 288-NYLCPAIINQIDARSCLIHTSEKKAEIPPKTYSLQIAWVGGFIAISIISF-337);
細胞外ループTM2-3(配列番号7 382-ASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWK-423);
細胞外ループTM4-5(配列番号8 619-TEGLSSG-625);
細胞外ループTM6-7(配列番号9 680-HYAENVSM-687);
細胞外C末端(配列番号10 748-KIVFRINF-755);
最も好ましくは、前記抗体は、輸送体のN末端全体に関して、すなわち切断事象より前に付番された以下の基準座標の間で、ZIP10の以下のECDの少なくとも1つを結合する。
N末端(配列番号12 164-EKETVEVSVKSDDKHMHDHNHRLRHHHRLHHHLDHNTHHFHNDSITPSERGEPSNEPSTETNKTQEQSDVKLPKGKRKKKGRKSNENSEVITPGFP-253);
N末端、(配列番号13 295-QDLDPDNEGELRHTRKREAPHVKNNAIISLR-395)
N末端、(配列番号14 36-LHRQHRGMTELEPSKFSKQAAENEKKYYIEKLFERYGENGRLSFFGLEKL-85)
細胞外ループTM2-3(配列番号15 465-GGHDHSHQHAHGHGHSHGHESNKFLEEYDAVLK-497);
細胞外ループTM4-5(配列番号16 693-SAGLTGG-699);
細胞外ループTM6-7(配列番号17 754-QYANNITLWN-762);
細胞外ループC末端(配列番号18 824-KIVFDIQF-831)。
材料、抗体及び処置
使用された抗体は、ZIP6-Y及びZIP10(自社);Santa Cruz BiotechnologyからのZIP6-SC(E-20、SC-84875)、pS727STAT3(SC-8001-R及びSC-136193)、pY705STAT3(SC-7993-R)、総STAT3(SC-8019)及びGAPDH(SC-32233);Cell Signalling Technologyからのα-チューブリン(DM1A、#3873S)、pS10ヒストンH3(#9706S及び#3377)及びpS38Stathmin(#4191);InvitrogenからのマウスV5;AbcamからのウサギV5(Ab9116);Sigma-Aldrichからのβ-アクチン(A5316)であった。
MCF-7細胞及びMCF-7細胞から発達させたタモキシフェン耐性細胞(TAMR)(1)を以前に記載されたとおりに(2)培養した。ホルマリン固定パラフィン包埋乳癌試料を脱脂し、再水和した後、pS727STAT3(SC-8001-R、1/650)又はpS10ヒストンH3(#3377、1/30)抗体とともに2時間インキュベートし、Dako Envision#K4011試薬で検出した。EDTAを加えたTris塩基中、pH9で2分間の加圧調理器を抗原賦活化のために使用した。使用した原乳癌材料は、適切な倫理的承認を有した(REC参照番号C2020313)。マウス腸組織の免疫組織化学は以前に記載されている(3)。
ベクターpcDNA3.1/V5-His-TOPOを使用した、C末端V5タグを有するZIP6/LIV-1/SLC39A6(4)及びZIP7/HKE4(5)のための組換え構築物の生成は、以前に記載されている。上記プラスミドからZIP6変異体(Y473A、S471A、S475A及びS478A、S479A)を生成し、配列決定によって確認した。記載されるように(6)、16時間、リポフェクタミンー2000(Life Technologies)で細胞を形質移入した。
形質移入の前に、厚さ0.17mmのカバーガラス上で1×105個の細胞を5~7日間成長させた。カバーガラスを固定し、前述のように(7)処理した。亜鉛画像化のために、細胞に5μM Fluozin-3(Invitrogen)を37℃で30分間負荷した。Becton-Dickinson FACSVerseを用いたFACS分析では、有糸分裂シェイクオフによって回収された非接着細胞及びトリプシン処理によって採集された接着細胞に5μM Fluozin-3(Invitrogen)を30分間負荷し、続いて培地中で30分間回収した。細胞周期分析では、細胞を70%エタノール中で一晩固定し、続いてFACS分析の前に、0.2μg/mL DNase-free RNaseAを加えた20μg/mLヨウ化プロピジウム(Sigma-Aldrich)及びPBS中の0.1%Triton X-100による37℃で20分間のDNA染色を行い、Watsonプラグマティックアルゴリズムを用いてFlowJo Softwareバージョン10で分析した。スケールバーは10μmである。
8ウェルチャンバースライド(Lab-Tek、Fisher)上の細胞を固定した後、以前に記載されたように(8)Duolink redキット(Sigma)を使用してPLAを行った。赤い蛍光の点は2分子結合を示す。少なくとも3つの異なる実験からの少なくとも12の別個の画像を使用してImageToolソフトウェア(Olink)によって細胞あたりのドットを決定し、平均値±標準誤差として提示した。
統計解析は、スチューデントのt-検定、又は事後ダネット及びテイムヘイン検定を用いたANOVAのいずれかを使用して行った。*=p<0.05、**=p<0.01、***=p<0.001として有意性を仮定した。エラーバーは、少なくとも3つの異なる実験による標準偏差(SD)である。
有糸分裂のためのZIP6及びZIP10の必要性。
ZIP6は、円形化した有糸分裂細胞中で濃縮されており(図5A)、本発明者らは、これらの有糸分裂細胞がpS727STAT3も含むことを発見した。本発明者らは、N末端切断及び細胞膜転位と合致するpY705STAT3の同時減少(図5B)及び増加した68kDa ZIP6バンドを伴うウェスタンブロットによって、有糸分裂において上昇したpS727STAT3を確認した(図5B)。さらに、亜鉛処理はSTAT3のリン酸化状態をpY705からpS727に変化させ(図5C)、これまでに有糸分裂の状況では報告されたことがない相互関係を実証している。しかしながら、有糸分裂におけるpS727STAT3のこの検出は、有糸分裂全ゲノム質量分析スクリーニングにおいても観察された。興味深いことに、pY705STAT3の喪失はSTAT3の転写活性を終結させ、転写は有糸分裂中に停止することが知られている。
有糸分裂過程とのpS727STAT3の時間的関連を分析するために、本発明者らは、有糸分裂中の細胞においてpS727STAT3を画像化した(図6A)。これにより、全ての有糸分裂段階でのpS727STAT3の存在が明らかになり、これは有糸分裂細胞におけるpS727STAT3の存在及びpY705STAT3の非存在によって確認され、細胞質分裂を受けている細胞がなおpS727STAT3について陽性であるが、pS10ヒストンH3については陰性であったことに注目すると、有糸分裂を通じてpS727STAT3が長期間存在することを示している。さらに、本発明者らは、ヒト乳癌の隣接するスライス片を使用して同じ細胞中のpS10ヒストンH3によって判断したところ、インビボで有糸分裂細胞中にpS727STAT3を検出した(図6B)。正常なマウス腸の有糸分裂細胞においてもpS727STAT3のさらなるインビボ染色が見られ(図6C)、正常な状態及び疾患状態を包含する有糸分裂中の一般的な過程であることが示唆された。
本発明者らは以前に、予想PEST部位における細胞膜への再転位のための必要条件としてZIP6のN末端切断を確立しており[7]、これらはしばしば細胞周期によって調節された様式でプロセシングされるので、本発明者らは、異なるエピトープを有するZIP6抗体を使用して有糸分裂中のいずれかのさらなる切断を調べた(図7A)。
本発明者らは、有糸分裂経路が活性化され得る前の、ZIP6/ZIP10ヘテロ二量体を介した亜鉛流入の必要性を示してきたが、これは、亜鉛が細胞増殖のために不可欠とされてきた理由、さらには、亜鉛欠乏が非常に有害であり得る理由を説明する。ZIP6又はZIP10抗体、特にこれらの輸送体のN末端を結合する抗体により有糸分裂を阻害する能力は、現在、癌及び線維症などの増殖性疾患を阻害するための新しい治療機会を提供する。
1.Knowlden,J.M.et al.Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.Endocrinology 144,1032-1044(2003)。
Claims (21)
- 抗有糸分裂組成物であって、有糸分裂を防止することによる過剰増殖性障害の処置において使用するために、少なくとも1つのZIP(Zrt、Irt様タンパク質)輸送体の細胞外ドメインを選択的に結合してその機能を阻害する少なくとも1つの抗体又はその断片を含み、前記ZIP輸送体は、ZIP6若しくはZIP10のいずれか、又はその両方を含むヘテロ二量体である、抗有糸分裂組成物。
- 前記断片が、前記抗体の少なくとも(1又は複数の)相補性決定領域を含む、請求項1に記載の抗有糸分裂組成物。
- 前記断片がアプタマーである、請求項1に記載の抗有糸分裂組成物。
- ZIP6についてはN末端1~325若しくは1~350及びZIP10については1~407の間で、またZIP6についてはN末端31~325若しくは31~350及びZIP10については31~407の間で、前記抗体が前記ZIP6及び/又はZIP10輸送体の細胞外ドメインを結合する、請求項1~3のいずれか一項に記載の抗有糸分裂組成物。
- 前記抗体が、ZIP6についてはN末端アミノ酸93~350及びZIP10については46~395の間で結合する、請求項1~4のいずれか一項に記載の抗有糸分裂組成物。
- 前記抗体が、ZIP6についてはN末端アミノ酸220~350及びZIP10については46~395の間で結合する、請求項1~5のいずれか一項に記載の抗有糸分裂組成物。
- 前記抗体が、ZIP6の以下のECD:
N末端エピトープ(配列番号1 93-HHDHDHHSDHEHHSD-107);
N末端エピトープ(配列番号2 246-EPRKGFMYSRNTNE-259);
N末端及び膜貫通ドメイン1を含む(配列番号3 301-RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN-350);
N末端(配列番号4 303-CLIHTSEKKAEIP-315);
N末端、(配列番号5 129-HSHHNHAASGKNKRKALCPDHDSDSSGKDPRNSQGKGAHRPEHASGRRNVKDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTSKSRVSRLAGRKTNESVSEPRKGFMYSRNTNENPQE-263);
N末端、(配列番号6 288-NYLCPAIINQIDARSCLIHTSEKKAEIPPKTYSLQIAWVGGFIAISIISF-337);
の1つ内に、又は
ZIP10の以下のECD:
N末端、(配列番号11 46-LEPSKFSKQAAENE-59);
N末端(配列番号12 164-EKETVEVSVKSDDKHMHDHNHRLRHHHRLHHHLDHNTHHFHNDSITPSERGEPSNEPSTETNKTQEQSDVKLPKGKRKKKGRKSNENSEVITPGFP-253);
N末端、(配列番号13 295-QDLDPDNEGELRHTRKREAPHVKNNAIISLR-395)
N末端、(配列番号14 36-LHRQHRGMTELEPSKFSKQAAENEKKYYIEKLFERYGENGRLSFFGLEKL-85)
の1つ内に結合する、請求項1~5のいずれか一項に記載の抗有糸分裂組成物。 - 前記抗体が、ZIP6M、ZIP6Y、ZIP6AM、ZIP6X、ZIP6R、抗SLC39A6a、抗SLC39A6b、抗SLC39A6c、抗SLC39A6d、LIV-1/ZIP6抗体、抗SLC39A6e、抗SLC39A6f、ZIP62-A、ZIP10、抗SLC39A10a、抗SLC39A10b、SLC39A10a、抗SLC39A10c及びSLC39A10bを含む群から選択される、請求項1~7のいずれか一項に記載の抗有糸分裂組成物。
- 前記抗体が、ZIP6Y、ZIP6AM、ZIP10及び抗SLC39A10aを含む群から選択される、請求項8に記載の抗有糸分裂組成物。
- 前記抗体が、ZIP6の以下の細胞外ループ:
細胞外ループTM2-3(配列番号7 382-ASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTWK-423);
細胞外ループTM4-5(配列番号8 619-TEGLSSG-625);
細胞外ループTM6-7(配列番号9 680-HYAENVSM-687);
細胞外C末端(配列番号10 748-KIVFRINF-755);
の少なくとも1つに結合する、
又は前記抗体が、ZIP10の以下の細胞外ループ:
細胞外ループTM2-3(配列番号15 465-GGHDHSHQHAHGHGHSHGHESNKFLEEYDAVLK-497);
細胞外ループTM4-5(配列番号16 693-SAGLTGG-699);
細胞外ループTM6-7(配列番号17 754-QYANNITLWN-762);
細胞外ループC末端(配列番号18 824-KIVFDIQF-831)
の少なくとも1つに結合する、請求項1~3のいずれか一項に記載の抗有糸分裂組成物。 - 少なくとも2つの抗体又はその断片が組み合わせて使用される、請求項1~10のいずれか一項に記載の抗有糸分裂組成物。
- 少なくとも1つの抗体が前記ZIP6輸送体の少なくとも一部を結合し、1つの抗体が前記ZIP10輸送体の少なくとも一部を結合する、請求項11に記載の抗有糸分裂組成物。
- 単一の抗体が、前記ZIP6:ZIP10ヘテロ二量体を結合してその機能を阻害する、請求項1~12のいずれか一項に記載の抗有糸分裂剤。
- 前記過剰増殖性障害が、癌及び固形腫瘍、リンパ腫又は白血病、乳癌、前立腺癌、結腸癌、脳癌、肺癌、膵臓癌、胃癌、膀胱癌及び腎臓癌などのその様々な形態;多発性嚢胞腎疾患(PKD)及び関連する嚢胞性腎疾患;黒色腫;過形成、化生及び異形成ならびにそれらの様々な形態;免疫系の増殖性障害(骨髄及びリンパ増殖性障害など);前立腺肥大症;子宮内膜症;乾癬;組織修復及び異常な創傷治癒;ならびに線維症、例えば、肺線維症、特発性肺線維症、肝硬変、心内膜心筋線維症、血管狭窄又は脊柱管狭窄、縦隔線維症、骨髄線維症、後腹膜線維症、進行性巨大線維症、腎性全身性線維症、クローン病、ケロイド又は陳旧性心筋梗塞、強皮症/全身性硬化症、関節線維症及び癒着性関節包炎などを含む群から選択される、請求項1~13のいずれか一項に記載の抗有糸分裂剤。
- 癌が、固形腫瘍、リンパ腫又は白血病、乳癌、前立腺癌、結腸癌、脳癌、肺癌、膵臓癌、胃癌、膀胱癌、食道癌及び腎臓癌から選択される、請求項1~14のいずれか一項に記載の抗有糸分裂組成物。
- 請求項1~15のいずれか一項に記載の抗有糸分裂組成物を薬学的に又は獣医学的に許容され得る賦形剤又は担体と一緒に含む、癌の処置において使用するための薬学的組成物又は獣医学的組成物。
- 少なくとも1つの他の治療剤と組み合わせた請求項1~15に記載の抗有糸分裂組成物を含む、過剰増殖性障害の処置において使用するための併用治療薬。
- 過剰増殖性障害を処置する方法であって、過剰増殖性障害を有する又は有することが疑われる対象に、請求項1~17のいずれか一項に記載の抗有糸分裂組成物又は併用治療薬が投与される、方法。
- 前記対象が哺乳動物である、請求項18に記載の方法。
- 前記哺乳動物が、ヒト、霊長類 ウマ、イヌ、ネコ、ブタ、ヒツジ、有蹄動物、又は任意の他の家庭用若しくは農業用の種である、請求項19に記載の方法。
- ZIP10に対して特異的である抗体又はその断片であって、前記抗体は、ZIP10輸送体のエピトープN末端46~59アミノ酸配列番号11 LEPSKFSKQAAENEに対して特異的である、抗体又はその断片。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1908208.0A GB201908208D0 (en) | 2019-06-10 | 2019-06-10 | An anti-mitotic agent |
GB1908208.0 | 2019-06-10 | ||
PCT/EP2020/065653 WO2020249483A1 (en) | 2019-06-10 | 2020-06-05 | Anti-mitotic composition comprising antibodies against zip6 and/or zip10 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022536476A true JP2022536476A (ja) | 2022-08-17 |
JPWO2020249483A5 JPWO2020249483A5 (ja) | 2022-11-17 |
Family
ID=67386342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021572873A Pending JP2022536476A (ja) | 2019-06-10 | 2020-06-05 | Zip6及び/又はzip10に対する抗体を含む抗有糸分裂組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220227861A1 (ja) |
EP (1) | EP3980457A1 (ja) |
JP (1) | JP2022536476A (ja) |
CN (1) | CN114206933A (ja) |
AU (1) | AU2020289952A1 (ja) |
CA (1) | CA3142661A1 (ja) |
GB (1) | GB201908208D0 (ja) |
WO (1) | WO2020249483A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012078688A2 (en) | 2010-12-06 | 2012-06-14 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040141983A1 (en) * | 1999-03-15 | 2004-07-22 | Protein Design Labs, Inc. | Compositions against cancer antigen LIV-1 and uses thereof |
AU2007238636A1 (en) * | 2006-04-13 | 2007-10-25 | Novartis Vaccines & Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancer |
KR20200090838A (ko) * | 2017-12-01 | 2020-07-29 | 시애틀 지네틱스, 인크. | 유방암 치료를 위한 인간화된 항-liv1 항체 |
-
2019
- 2019-06-10 GB GBGB1908208.0A patent/GB201908208D0/en not_active Ceased
-
2020
- 2020-06-05 CN CN202080056383.8A patent/CN114206933A/zh active Pending
- 2020-06-05 US US17/618,116 patent/US20220227861A1/en active Pending
- 2020-06-05 CA CA3142661A patent/CA3142661A1/en active Pending
- 2020-06-05 AU AU2020289952A patent/AU2020289952A1/en active Pending
- 2020-06-05 WO PCT/EP2020/065653 patent/WO2020249483A1/en active Search and Examination
- 2020-06-05 EP EP20731833.8A patent/EP3980457A1/en active Pending
- 2020-06-05 JP JP2021572873A patent/JP2022536476A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114206933A (zh) | 2022-03-18 |
CA3142661A1 (en) | 2020-12-17 |
EP3980457A1 (en) | 2022-04-13 |
WO2020249483A1 (en) | 2020-12-17 |
GB201908208D0 (en) | 2019-07-24 |
US20220227861A1 (en) | 2022-07-21 |
AU2020289952A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10966985B2 (en) | Macrocyclic compounds as ROS1 kinase inhibitors | |
AU2014224608B2 (en) | Combination therapy for neoplasia treatment | |
WO2019126398A1 (en) | Wnt surrogate molecules and uses thereof | |
US20200206344A1 (en) | Methods for modulating the interaction between ews-fli1 and baf complexes | |
JP2005139121A (ja) | p38/JTV−1を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法 | |
US11273160B2 (en) | RET inhibitor for use in treating cancer having a RET alteration | |
US20190055563A1 (en) | Polymerase q as a target in hr-deficient cancers | |
JP2022536476A (ja) | Zip6及び/又はzip10に対する抗体を含む抗有糸分裂組成物 | |
KR20120105429A (ko) | 염증 치료 방법 | |
JP2016516005A (ja) | 新規のアンドロゲンレセプター変異 | |
US20160045598A1 (en) | Combination Treatments with Sonic Hedgehog Inhibitors | |
US20210290620A1 (en) | Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity | |
EP2845588A1 (en) | PIN1 inhibitors for use in the prevention and/or treatment of theileriosis, and related applications | |
EP3969000B1 (en) | Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation | |
US20220288067A1 (en) | Treatment of cancer with cdk inhibitors | |
US20230338466A1 (en) | Compositions and methods comprising r-spondins for treatment of tumors | |
Schott et al. | GAS6 and AXL promote insulin resistance by rewiring insulin signaling and increasing insulin receptor trafficking to late endosomes | |
US20230293649A1 (en) | Cst6, cells expressing cst6 and methods of use | |
JP7254020B2 (ja) | 融合遺伝子を含有するがんを治療する方法 | |
US20190314470A1 (en) | Methods Of Disrupting Ras-Driven Cancer Growth Using Engineered Bacterial Snare-Cleaving Toxins | |
WO2023230549A2 (en) | Compositions and methods for modulation of tumor suppressors and oncogenes | |
WO2023230570A2 (en) | Compositions and methods for modulating genetic drivers | |
WO2022066502A1 (en) | Notch1 biomarkers for cancer therapy | |
Chan | Generation of Engineered Small Protein Scaffolds and Insulin Receptor Targeting in Human Breast Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20220207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230508 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230818 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240507 |